US SEC Trading Suspension Halt Orders — March 19, 2026

Closing bid price below $1.00 for 30 consecutive business days (recent 30-day trend), Nasdaq notice under Rule 5550(a)(2), hearing requested with stay but no compliance assurance

Common stock (SKYE) below $1.00 minimum bid for 30 consecutive business days (30-day price decline), 180-day cure period to Sept 14, 2026, reverse split required if no natural recovery

Average Class A closing price below $1.00 over 30 consecutive trading days (30-day VWAP decline), NYSE Section 802.01C violation, six-month cure with no immediate halt

Emerging growth company status offers no delisting protection, hearing under Rule 5810(c)(3)(A)(iv) with up to 180-day extension possible but uncertain

Compliance requires $1.00+ closes for 10 consecutive business days within 180 days, reverse split deadline 10 business days pre-Sept 14, trading uninterrupted but risk escalates

Cure demands $1.00 closing price and 30-day average on last trading day of any cure month, plans notification to NYSE within 10 business days

Identical 30-day sub-$1 price trend across Nasdaq/NYSE, no period-over-period price recovery, signaling uniform underperformance vs. listing minima

Automatic delisting stay via hearing request, but panel relief not guaranteed, heightening uncertainty

Nasdaq Listing Qualifications Dept. notice dated March 17, 2026, potential transfer to delisting queue post-cure failure

References 10-K risk factors (Dec 31, 2025), Exhibit 99.1 press release signals public acknowledgment of weakness

No insider buying or positive capital allocation mentioned amid price collapse, contrasting potential conviction signals

Negative sentiment uniform at 9/10 materiality, no bullish forward-looking operational guidance to counter delisting pressure

Nasdaq non-compliance notice March 13, 2026, hearing outcome uncertain, potential 180-day extension but no listing maintenance guarantee

30-day bid < $1.00 with no assurance of regaining via market or reverse split by Sept 14, 2026, risking transfer/review

Must hit $1.00 close + 30-day avg in six months from March 17, 2026, or face delisting despite ongoing trading

Uniform QoQ price decline below $1.00 for exactly 30 days, indicating accelerated weakness vs. prior periods

Rule 5810(c)(3)(A)(iv) process stays delisting but panel denial could trigger immediate action

Mandatory if no compliance, dilutive with deadline 10 bus days pre-cure end, operational continuity unimpacted but shareholder value at risk

Cure plans due to NYSE within 10 bus days (by ~March 31, 2026), delay signals weak strategy

Absence of insider purchases, buybacks, or positive guidance amid notices, deteriorating conviction

Trading continues now but failure leads to suspensions/delisting/OTC, amplifying liquidity risks

Ties to 2025 10-K risks, no new forward-looking operational improvements cited

Monitor panel decision for potential 180-day extension grant, short-term bounce if relief signaled

Announcement of split (due by early Sept 2026) often sparks technical rallies/squeezes in sub-$1 names

Disclosure within 10 bus days (~March 31, 2026) could reveal buyback/restructuring, trading pop on positive details

No immediate suspensions enable options/short strategies on heightened vol from delisting overhang

10 consec days at $1+ within 180-day period offers binary upside if biotech catalysts emerge

Last trading day of any cure month for $1+ close/avg provides repeated re-rating chances

Uniform negative sentiment + no insider support positions for downside on cure failures, relative outperformance vs. compliant peers

EGC status may aid flexible compliance paths post-hearing, undervalued if tech rebound

All 3 filings cite exactly 30-day consecutive declines below $1.00 (Nasdaq/NYSE), cross-sector (tech/biotech/media) small-cap distress implying broad market pressure on low-float names

180 days (Skye/AVAX potential), six months (Getty), vs. standard; allows trading continuity but builds dilution risk via reverse splits

Uniform across exchanges, preserving liquidity short-term but escalating delisting queues; aggregate 9/10 materiality flags systemic OTC migration risk

Explicit (Skye) and implied paths dominate forward-looking compliance, historical pattern shows post-split fades; watch for cluster announcements

AVAX stay via hearing, Getty 10-day plan disclosure; differentiates Nasdaq urgency vs. NYSE flexibility, potential for staggered volatility

No enriched period comps (revenue/margins), insider activity, or cap alloc trends cited positively, highlighting pure price-driven risks over fundamentals

Panel decision on delisting stay/extension, up to 180 days possible; monitor for grant/denial [TBD 2026]

Regain $1.00 bid for 10 consec days or reverse split by Sept 14, 2026; track monthly closes [Sept 14, 2026]

NYSE notification of compliance strategy within 10 bus days [~March 31, 2026]

Last trading day of each calendar month in six-month period for $1.00 close/30-day avg [Monthly thru ~Sept 2026]

Daily bid/closing prices vs. $1.00 threshold post-notice, for early compliance or further decline [Ongoing]

Implementation no later than 10 bus days pre-Sept 14, 2026; watch for filing/approval [Q3 2026]

Nasdaq Hearings Panel ruling under Rule 5810(c)(3)(A)(iv), impacts listing fate [Within weeks/months]

Emerging buys/sells post-notice to gauge conviction amid no current data [Ongoing 30 days]